Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Colorectal Neoplasms 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Fluorouracil 61Leucovorin 56Oxaliplatin 36Irinotecan 27Specimen Handling 23Biopsy 20Chemotherapy, Adjuvant 17Capecitabine 14Cetuximab 13Magnetic Resonance Spectroscopy 12Folfox protocol 12Bevacizumab 12Neoadjuvant Therapy 10sargramostim 6aldesleukin 6Melphalan 6Radiotherapy 5Floxuridine 5Cyclophosphamide 5dehydroftorafur 4X-Rays 4Nivolumab 4Interferon-alpha 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Celecoxib 4fludarabine 3durvalumab 3Trastuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Colorectal Neoplasms × CX 5461 × Clear all
NCT07147231 2026-05-13

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

National Cancer Institute (NCI)

Phase 1/2 Recruiting
86 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡